AP NEWS
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Ultivue releases breakthrough innovations for multiplex IHC: 16-marker whole-slide visualization and high marker co-localization in FFPE tissue

March 28, 2019
Ultivue 16-plex IHC assay staining NSCLC tissue (Photo: Business Wire)

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar 28, 2019--Ultivue today unveiled the expanded capabilities of its proprietary InSituPlex® DNA-barcoding and staining technology through comprehensive visualization of a whole slide 16-marker multiplex assay in tissue. Until now, this level of multiplexing relied on complex instrumentation to map marker location or was limited to visualizing specific regions of interest. Ultivue’s demonstrated capabilities now enable researchers to visualize and spatially profile a high level of multiplexing on a whole slide, in one work day.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190328005516/en/

Ultivue 16-plex IHC assay staining NSCLC tissue (Photo: Business Wire)

“Ultivue is now able to offer solutions for a full range of scientific interests, from Discovery, to Translational and into Clinical research fields,” said Michael Natan, CEO of Ultivue. “This recent development opens up a new level of strategic engagement with our customers centered around the identification of complex biomarker signatures and the demonstration of clinical utility of high-plex panels for patient stratification.”

Data generated from this 16-marker assay also showed the co-localization of 5 markers in the same cellular compartment. “This level of specificity on individual cells enables researchers to confidently identify and characterize complex cell phenotypes that would otherwise remain undetected or only partially identified,” added Philippe Mourere, SVP Commercial Operations.

The data highlighting the science behind the 16-plex assay will be one of six posters showcasing the capabilities and applications of the InSituPlex technology on display at the American Association for Cancer Research (AACR) annual meeting. Details of the poster sessions can be found below:

Monday, April 1, 8 AM-12 PM

  • Poster # 1179 - Deep spatial immuno-profiling through high biomarker colocalization in FFPE tumor tissue sections
  • Poster # 1183 - High-plex spatial profiling of whole FFPE tissue sections using InSituPlex technology for discovery applications
  • Poster # 1187 - Toward high-throughput, high-multiplex FFPE tumor tissue assays for translational research: 7-color, whole slide imaging
  • Poster # 1677 - Understanding the TME: Advanced analysis and visualization of multiplexed fluorescence images

Wednesday, April 3, 8 AM-12 PM

  • Poster # 4569 - Intra- and inter-run assessment of reproducibility and quantification of UltiMapper I/O APC and T-act kits for tissue multiplexing
  • Poster # 4555 - Characterization of the tumor microenvironment with an automated 10-plex IHC panel using UltiMapper I/O assays

Ultivue’s team will be available to engage with the scientific community at booth #2048 throughout the AACR conference.

About Ultivue
By developing novel, proprietary reagents used both for biomarker discovery (higher content, low throughput) and translational use (lower content, high throughput), Ultivue is connecting the insights gained from research directly into the pathology lab. Ultivue’s UltiMapper™ multiplexed assays applied to tissue biopsy samples enable simultaneous quantitation of multiple biomarkers with sub-cellular spatial resolution and fit completely within traditional IHC workflows. Translational and clinical researchers leverage UltiMapper™ assays to elucidate complex biology and demonstrate their clinical utility as precision medicine research tools. Ultivue is expanding its UltiMapper™ assay product portfolio and menu of contract research services to provide a comprehensive set of personalized medicine solutions for research in oncology research and other therapeutic areas.

Ultivue is based in Cambridge, MA. For more information, visit www.ultivue.com

For Research Use Only. Not for use in diagnostic procedures.

View source version on businesswire.com:https://www.businesswire.com/news/home/20190328005516/en/

CONTACT: Louis Levy

+1-617-945-2662

contact@ultivue.com

KEYWORD: UNITED STATES NORTH AMERICA MASSACHUSETTS

INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY GENETICS ONCOLOGY RESEARCH SCIENCE

SOURCE: Ultivue

Copyright Business Wire 2019.

PUB: 03/28/2019 09:35 AM/DISC: 03/28/2019 09:35 AM

http://www.businesswire.com/news/home/20190328005516/en